ATE499368T1 - Chinolonverbindung und pharmazeutische zusammensetzung - Google Patents

Chinolonverbindung und pharmazeutische zusammensetzung

Info

Publication number
ATE499368T1
ATE499368T1 AT08765545T AT08765545T ATE499368T1 AT E499368 T1 ATE499368 T1 AT E499368T1 AT 08765545 T AT08765545 T AT 08765545T AT 08765545 T AT08765545 T AT 08765545T AT E499368 T1 ATE499368 T1 AT E499368T1
Authority
AT
Austria
Prior art keywords
pharmaceutical composition
quinolone compound
quinolone
compound
pharmaceutical
Prior art date
Application number
AT08765545T
Other languages
English (en)
Inventor
Kenji Otsubo
Yuji Ochi
Masami Nakai
Atsushi Mori
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Application granted granted Critical
Publication of ATE499368T1 publication Critical patent/ATE499368T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/40—Nitrogen atoms attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
AT08765545T 2007-06-06 2008-06-06 Chinolonverbindung und pharmazeutische zusammensetzung ATE499368T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007150819 2007-06-06
PCT/JP2008/060804 WO2008150029A1 (en) 2007-06-06 2008-06-06 Quinolone compound and pharmaceutical composition

Publications (1)

Publication Number Publication Date
ATE499368T1 true ATE499368T1 (de) 2011-03-15

Family

ID=39730840

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08765545T ATE499368T1 (de) 2007-06-06 2008-06-06 Chinolonverbindung und pharmazeutische zusammensetzung

Country Status (28)

Country Link
US (5) US8269011B2 (de)
EP (1) EP2152699B1 (de)
JP (1) JP5063708B2 (de)
KR (4) KR101403817B1 (de)
CN (1) CN101679392B (de)
AR (1) AR066872A1 (de)
AT (1) ATE499368T1 (de)
AU (1) AU2008260867B2 (de)
BR (1) BRPI0812234A2 (de)
CA (1) CA2688448C (de)
CO (1) CO6270258A2 (de)
CY (1) CY1111936T1 (de)
DE (1) DE602008005137D1 (de)
DK (1) DK2152699T3 (de)
ES (1) ES2360572T3 (de)
HK (1) HK1139153A1 (de)
HR (1) HRP20110151T1 (de)
IL (1) IL201894A (de)
MX (1) MX2009013239A (de)
MY (1) MY148098A (de)
NZ (1) NZ580919A (de)
PL (1) PL2152699T3 (de)
PT (1) PT2152699E (de)
RU (1) RU2490259C2 (de)
SI (1) SI2152699T1 (de)
TW (1) TWI366565B (de)
UA (1) UA98789C2 (de)
WO (1) WO2008150029A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI366565B (en) * 2007-06-06 2012-06-21 Otsuka Pharma Co Ltd Quinolone compound and pharmaceutical composition
US20110251180A1 (en) * 2008-12-05 2011-10-13 Otsuka Pharmaceutical Co., Ltd. Pharmaceutical agent comprising quinolone compound
WO2010065905A2 (en) * 2008-12-05 2010-06-10 Oregon Health & Science University Compounds having antiparasitic or anti-infectious activity
TWI492943B (zh) 2008-12-05 2015-07-21 大塚製藥股份有限公司 喹啉酮化合物及藥學組成物（二）
US8598354B2 (en) * 2008-12-05 2013-12-03 University Of South Florida Compounds having antiparasitic or anti-infectious activity
EP2509414B1 (de) * 2009-12-09 2017-08-09 Barlaa B.V. Mikrokolloidale kieselsäure-/borsäurezusammensetzung und verfahren zur herstellung einer bioverstärkenden lösung und pulver
JP5769504B2 (ja) * 2010-06-04 2015-08-26 大塚製薬株式会社 医薬
WO2012066330A1 (en) 2010-11-17 2012-05-24 Heptares Therapeutics Limited Compounds useful as a2a receptor inhibitors
WO2017112678A1 (en) 2015-12-21 2017-06-29 Rima Mcleod Compounds and methods for treating, detecting, and identifying compounds to treat apicomplexan parasitic diseases

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3416695A1 (de) 1984-05-05 1985-11-07 Bayer Ag, 5090 Leverkusen Amidinohydrazone von tetralin-, chromon-, thiochromon- und tretrahydrochinolin-derivaten, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
DE68917024D1 (de) * 1988-05-24 1994-09-01 Kirin Brewery 4(1H)-Chinolonderivate.
GB9022785D0 (en) 1990-10-19 1990-12-05 Merck Sharp & Dohme Therapeutic agents
GB9026389D0 (en) 1990-12-05 1991-01-23 Merck Sharp & Dohme Therapeutic agents
MX9200299A (es) 1991-02-07 1992-12-01 Roussel Uclaf Nuevos derivados biciclicos nitrogenados, su procedimiento de preparacion los nuevos compuestos intermedios obtenidos su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen.
GB9125515D0 (en) 1991-11-29 1992-01-29 Merck Sharp & Dohme Therapeutic agents
GB9125485D0 (en) 1991-11-29 1992-01-29 Merck Sharp & Dohme Therapeutic agents
PL173618B1 (pl) 1992-10-30 1998-04-30 Pfizer Związki 6-[2-(4-hydroksy-4-fenylopiperydyno)-1-hydroksypropylo]-3,4-dihydro-2(1H)-chinolonowe
FR2709489B1 (fr) 1993-08-31 1995-10-20 Adir Nouveaux dérivés de 2-(1H)-quinoléinone, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
EP0933351A1 (de) 1994-12-30 1999-08-04 Ligand Pharmaceuticals Incorporated Tricyclische Retinoide, Verfahren zu ihrer Herstellung und ihre Verwendung
GB9621757D0 (en) 1996-10-18 1996-12-11 Ciba Geigy Ag Phenyl-substituted bicyclic heterocyclyl derivatives and their use
AU7165798A (en) 1997-04-28 1998-11-24 Anticancer, Inc. Use of genistein and related compounds to treat certain sex hormone related conditions
IT1296985B1 (it) 1997-12-19 1999-08-03 Zambon Spa Derivati benzazinici inibitori della fosfodiesterasi 4
FR2784988B1 (fr) * 1998-10-23 2002-09-20 Adir Nouveaux composes dihydro et tetrahydroquinoleiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2000042026A1 (en) 1999-01-15 2000-07-20 Novo Nordisk A/S Non-peptide glp-1 agonists
CN1358091A (zh) 1999-04-16 2002-07-10 阿斯特拉曾尼卡有限公司 雌激素受体－β配体
ES2235883T3 (es) 1999-05-06 2005-07-16 Neurogen Corporation 4-oxo-quinolino-3-carboxamidas sustituidas: ligandos de receptores cerebrales gaba.
FR2797444B1 (fr) 1999-08-13 2003-02-07 Lafon Labor Compositions pharmaceutiques comprenant des 4-quinolones
AUPQ266199A0 (en) 1999-09-06 1999-09-30 Novogen Research Pty Ltd Compositions and therapeutic methods involving isoflavones and analogues thereof
TWI243173B (en) 1999-11-17 2005-11-11 Akzo Nobel Nv Spiro[2H-1-benzopyran-2,4'-piperidine] derivatives
FR2813791B1 (fr) 2000-09-14 2004-03-12 Lafon Labor Utilisation de 2- et 4-quinolones pour inhiber la neo-proliferation intimale
GB0023918D0 (en) 2000-09-29 2000-11-15 King S College London Antiparasitic compounds
WO2002030407A1 (en) 2000-10-13 2002-04-18 Astrazeneca Ab ESTROGEN RECEPTOR-β LIGANDS
EP1368024A4 (de) 2001-03-16 2009-03-18 Novogen Res Pty Ltd Behandlung von restenose
AUPR846401A0 (en) 2001-10-25 2001-11-15 Novogen Research Pty Ltd 6-Hydroxy isoflavones, derivatives and medicaments involving same
SE0103648D0 (sv) * 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic quinolone compounds
AU2002950217A0 (en) 2002-07-16 2002-09-12 Prana Biotechnology Limited 8- Hydroxy Quinoline Derivatives
US20040033480A1 (en) 2002-08-15 2004-02-19 Wong Norman C.W. Use of resveratrol to regulate expression of apolipoprotein A1
US20050080024A1 (en) 2002-08-15 2005-04-14 Joseph Tucker Nitric oxide donating derivatives for the treatment of cardiovascular disorders
GB0222516D0 (en) 2002-09-27 2002-11-06 Karobio Ab Novel compounds
US20070037848A1 (en) 2003-04-03 2007-02-15 Masters Colin L Treatment of neurological conditions
US7183413B2 (en) 2003-04-11 2007-02-27 Taigen Biotechnology Aminoquinoline compounds
US20060025337A1 (en) 2003-07-01 2006-02-02 President And Fellows Of Harvard College Sirtuin related therapeutics and diagnostics for neurodegenerative diseases
AU2004279644A1 (en) 2003-10-10 2005-04-21 Resverlogix Corp. Treatment of diseases associated with the egr-1 enhancer element
MXPA06005697A (es) 2003-11-19 2006-08-17 Novogen Res Pty Ltd Composiciones y metodos para radioterapia y quimioterapia en combinacion.
KR100636423B1 (ko) * 2004-04-30 2006-10-19 한국화학연구원 신규한 퀴놀리논 유도체, 이의 제조방법 및 이를유효성분으로 하는 약학적 조성물
ATE497809T1 (de) * 2004-05-18 2011-02-15 Bright Future Pharmaceutical Lab Ltd Myricitrin verbindungen zur behandlung von schlafstörungen
GB0420702D0 (en) * 2004-09-17 2004-10-20 Univ Birmingham Use of methanofullerene derivatives as resist materials and method for forming a resist layer
US7846915B2 (en) 2004-10-20 2010-12-07 Resverlogix Corporation Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
EP1886996A1 (de) 2006-08-10 2008-02-13 Ferrer Internacional, S.A. 1H-Chinolin-4-on Verbindungen mit Affinität für den GABA Rezeptor, Prozesse, Verwendungen und Zusammensetzungen
TWI366565B (en) 2007-06-06 2012-06-21 Otsuka Pharma Co Ltd Quinolone compound and pharmaceutical composition
WO2009053799A1 (en) 2007-10-24 2009-04-30 Glenmark Pharmaceuticals, S.A. Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
US20110251180A1 (en) * 2008-12-05 2011-10-13 Otsuka Pharmaceutical Co., Ltd. Pharmaceutical agent comprising quinolone compound
TWI492943B (zh) * 2008-12-05 2015-07-21 大塚製藥股份有限公司 喹啉酮化合物及藥學組成物（二）

Also Published As

Publication number Publication date
PT2152699E (pt) 2011-04-04
IL201894A (en) 2013-07-31
DK2152699T3 (da) 2011-04-18
KR20140097570A (ko) 2014-08-06
HRP20110151T1 (hr) 2011-05-31
RU2490259C2 (ru) 2013-08-20
CA2688448A1 (en) 2008-12-11
HK1139153A1 (en) 2010-09-10
NZ580919A (en) 2011-12-22
JP5063708B2 (ja) 2012-10-31
US20150218101A1 (en) 2015-08-06
MY148098A (en) 2013-02-28
CA2688448C (en) 2015-11-24
DE602008005137D1 (de) 2011-04-07
AU2008260867B2 (en) 2011-03-17
US20120316168A1 (en) 2012-12-13
CN101679392B (zh) 2012-05-30
JP2010528982A (ja) 2010-08-26
US20140121207A1 (en) 2014-05-01
US8642619B2 (en) 2014-02-04
UA98789C2 (ru) 2012-06-25
US9045464B2 (en) 2015-06-02
AR066872A1 (es) 2009-09-16
KR20120012987A (ko) 2012-02-13
KR101154613B1 (ko) 2012-06-08
KR101403817B1 (ko) 2014-06-03
TW200900382A (en) 2009-01-01
BRPI0812234A2 (pt) 2014-12-16
TWI366565B (en) 2012-06-21
KR20140021723A (ko) 2014-02-20
KR101472262B1 (ko) 2014-12-11
KR101536883B1 (ko) 2015-07-14
PL2152699T3 (pl) 2011-07-29
MX2009013239A (es) 2010-01-25
CO6270258A2 (es) 2011-04-20
RU2009149612A (ru) 2011-07-20
US20160304461A1 (en) 2016-10-20
US20100130546A1 (en) 2010-05-27
EP2152699A1 (de) 2010-02-17
KR20100028093A (ko) 2010-03-11
US9403773B2 (en) 2016-08-02
WO2008150029A1 (en) 2008-12-11
CY1111936T1 (el) 2015-11-04
US8269011B2 (en) 2012-09-18
AU2008260867A1 (en) 2008-12-11
IL201894A0 (en) 2010-06-16
EP2152699B1 (de) 2011-02-23
SI2152699T1 (sl) 2011-05-31
CN101679392A (zh) 2010-03-24
ES2360572T3 (es) 2011-06-07

Similar Documents

Publication Publication Date Title
LTC2140867I2 (lt) Farmacinė kompozicija
BRPI0923836A2 (pt) Composições farmacêuticas orais contendo opióide e métodos
BRPI0715712A2 (pt) Composição farmacêutica
BRPI0721651A2 (pt) Composição farmacêutica
BRPI0719393A2 (pt) Composição farmacêutica
ATE493119T1 (de) Pharmazeutische zusammensetzung
DK3492069T3 (da) Farmaceutiske sammensætninger omfattende jern-oxy-hydroxid
ATE542815T1 (de) Kokristalle und pharmazeutische zusammensetzungen damit
BRPI0819232A2 (pt) composto heterocíclico e composição farmacêutica do mesmo
BRPI0716445A2 (pt) composiÇço farmacÊutica
BRPI0720234A2 (pt) Composição farmacêutica
BRPI0908132A2 (pt) Composto de benzodiazepina e composição farmacêutica
BRPI0817833A2 (pt) Composição farmacêutica antimalárica
ATE499368T1 (de) Chinolonverbindung und pharmazeutische zusammensetzung
BRPI0807078A2 (pt) Composto, e, formulação farmacêutica
LTPA2020538I1 (lt) Chinolinonų dariniai ir jų farmacinės kompozicijos
ATE530546T1 (de) Kokristalle und pharmazeutische zusammensetzungen damit
IL232458A0 (en) Quinolone compound and pharmaceutical preparation
BRPI0912074A2 (pt) composto e composição farmacêutica
ATE540672T1 (de) Pharmazeutische zusammensetzung und verfahren
DK2231603T3 (da) Substituerede 3-hydroxypyridiner og farmaceutiske sammensætninger deraf
BRPI0820839A2 (pt) Composição farmacêutica
TH0801002797A (th) สารประกอบควินอโลน และองค์ประกอบทางเภสัชกรรม
BRPI0917550A2 (pt) derivado de aminopropilideno e composição farmacêutica compreendendo o referido derivado
ITMI20061734A1 (it) Composizione farmaceutica

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2152699

Country of ref document: EP